In vitro activity of 23 antifungal drugs against 54 clinical and environmental Aspergillus oryzae isolates
Abstract The treatment of invasive aspergillosis caused by cryptic species remains a challenge due to the lack of randomised clinical trials and investigation of the efficacy and safety of different therapeutic strategies. We aimed to evaluate the in vitro activity of 23 conventional and new antifungal drugs against 54 clinical and environmental Aspergillus oryzae isolates by using the Clinical and Laboratory Standards Institute (CLSI) standard M38‐A3. The lowest geometric mean MIC values were found for luliconazole and lanoconazole (0.001 μg/ml), followed by anidulafungin (0.104 μg/ml), posaconazole (0.15 μg/ml), itraconazole (0.37 μg/ml), efinaconazole (0.5 μg/ml), voriconazole (0.51 μg/ml), tavaborole (0.72 μg/ml), and amphotericin B (0.79 μg/ml). In contrast, ketoconazole, terbinafine, econazole, tioconazole, ravuconazole, miconazole, nystatin, clotrimazole, griseofulvin, sertaconazole, natamycin, tolnaftate, and fluconazole had no or low activity. Further studies are required to determine how well this in vitro activity translates into in vivo efficacy..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:65 |
|---|---|
| Enthalten in: |
Mycoses - 65(2022), 11, Seite 981-988 |
| Beteiligte Personen: |
Abastabar, Mahdi [VerfasserIn] |
|---|
| BKL: |
|---|
| Anmerkungen: |
© 2022 Wiley‐VCH GmbH. |
|---|
| Umfang: |
8 |
|---|
| doi: |
10.1111/myc.13481 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY011229373 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY011229373 | ||
| 003 | DE-627 | ||
| 005 | 20230307223443.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230218s2022 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/myc.13481 |2 doi | |
| 028 | 5 | 2 | |a MYC_MYC13481.xml |
| 035 | |a (DE-627)WLY011229373 | ||
| 035 | |a (WILEY)MYC13481 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.75 |2 bkl | ||
| 084 | |a 44.93 |2 bkl | ||
| 100 | 1 | |a Abastabar, Mahdi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a In vitro activity of 23 antifungal drugs against 54 clinical and environmental Aspergillus oryzae isolates |
| 264 | 1 | |c 2022 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2022 Wiley‐VCH GmbH. | ||
| 520 | |a Abstract The treatment of invasive aspergillosis caused by cryptic species remains a challenge due to the lack of randomised clinical trials and investigation of the efficacy and safety of different therapeutic strategies. We aimed to evaluate the in vitro activity of 23 conventional and new antifungal drugs against 54 clinical and environmental Aspergillus oryzae isolates by using the Clinical and Laboratory Standards Institute (CLSI) standard M38‐A3. The lowest geometric mean MIC values were found for luliconazole and lanoconazole (0.001 μg/ml), followed by anidulafungin (0.104 μg/ml), posaconazole (0.15 μg/ml), itraconazole (0.37 μg/ml), efinaconazole (0.5 μg/ml), voriconazole (0.51 μg/ml), tavaborole (0.72 μg/ml), and amphotericin B (0.79 μg/ml). In contrast, ketoconazole, terbinafine, econazole, tioconazole, ravuconazole, miconazole, nystatin, clotrimazole, griseofulvin, sertaconazole, natamycin, tolnaftate, and fluconazole had no or low activity. Further studies are required to determine how well this in vitro activity translates into in vivo efficacy. | ||
| 700 | 1 | |a Zaedi, Arezoo |4 aut | |
| 700 | 1 | |a Shabanzadeh, Shafigheh |4 aut | |
| 700 | 1 | |a Nosratabadi, Mohsen |4 aut | |
| 700 | 1 | |a Moazeni, Maryam |4 aut | |
| 700 | 1 | |a Aghili, Seyed Reza |4 aut | |
| 700 | 1 | |a Haghani, Iman |4 aut | |
| 700 | 1 | |a Khojasteh, Shaghayegh |4 aut | |
| 700 | 1 | |a Javidnia, Javad |4 aut | |
| 700 | 1 | |a Nargesi, Sanaz |4 aut | |
| 700 | 1 | |a Shokohi, Tahereh |4 aut | |
| 700 | 1 | |a Hedayati, Mohammad Taghi |4 aut | |
| 700 | 1 | |a Meis, Jacques F. |4 aut | |
| 700 | 1 | |a Badali, Hamid |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Mycoses |g 65(2022), 11, Seite 981-988 |w (DE-627)WLY011225513 |x 14390507 |7 nnns |
| 773 | 1 | 8 | |g volume:65 |g year:2022 |g number:11 |g pages:981-988 |g extent:8 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 936 | b | k | |a 44.75 |q ASE |
| 936 | b | k | |a 44.93 |q ASE |
| 951 | |a AR | ||
| 952 | |d 65 |j 2022 |e 11 |h 981-988 |g 8 | ||